BRIEF-Sobi and Biogen's Elocta approved in Europe for the treatment of haemophilia A

* Says Sobi and Biogen's Elocta (rfviiifc) approved in Europe for the treatment of haemophilia a
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.